Tin tức & Cập nhật

A test-negative, case-control study demonstrated the real-world effectiveness of the BNT162b2 vaccine (Pfizer–BioNTech) and mRNA-1273 vaccine (Moderna) among healthcare personnel in the US.

People who had an allergic response to the first dose of COVID-19 vaccination or who believe they will have an allergy to vaccination should not let their worries delay getting vaccinated — as most of them can still be fully vaccinated safely, suggest studies presented at ACAAI 2021.

It is rare to achieve successful home noninvasive ventilation (NIV) in real life, reports a recent study. To improve patient-centred outcomes, health-related quality of life (HRQOL) and NIV tolerance must then be assessed.

The anti-PD-1 antibody nivolumab demonstrated potential as a treatment alternative for relapsed malignant mesothelioma that has progressed following first-line chemotherapy (CT), the phase III CONFIRM* trial has shown.

Young adults with chronic respiratory symptoms are at high risk of cardiovascular disease (CVD) and all-cause mortality in midlife, with the risk increase independent of established cardiovascular risk factors, smoking and lung function, a study reports.

Late introduction of eggs, along with less frequent egg consumption, may place a child at increased risk of egg allergy during childhood, suggests a study presented at ACAAI 2021.

Use of nintedanib in the treatment of interstitial lung disease (ILD) appears to delay its progression in Japanese patients, independent of the fibrotic pattern on high-resolution computed tomography (HRCT), as shown in a subgroup analysis of the phase III INBUILD trial.

The COVID-19 pandemic has forced people to wear mask to prevent the spread of the disease, but the increasing prevalence of masking has also resulted in a reduction in emergency department (ED) visits for other viral illnesses and exacerbations of asthma and chronic obstructive pulmonary disease (COPD), according to a US study.

The combination immunotherapy of nivolumab (NIVO) and ipilimumab (IPI) continues to provide durable survival benefit over chemotherapy in the first-line setting in patients with unresectable malignant pleural mesothelioma (MPM), despite the patients having been off immunotherapy for 1 year, according to the 3-year data from the CheckMate 743 trial presented at ESMO 2021.